WO2024261775 - A DRUG-ANTAGONIST COMBINATION DOSAGE FORM
National phase entry is expected:
Publication Number
WO/2024/261775
Publication Date
26.12.2024
International Application No.
PCT/IN2024/050851
International Filing Date
16.06.2024
Title **
[English]
A DRUG-ANTAGONIST COMBINATION DOSAGE FORM
[French]
FORME POSOLOGIQUE COMBINÉE D'ANTAGONISTE ET DE MÉDICAMENT
Applicants **
PATEL, Jayendrakumar Dasharathlal
26, R V Bunglows, Manipura Road
Vijapur 382870, IN
Inventors
PATEL, Jayendrakumar Dasharathlal
26, R V Bunglows, Manipura Road
Vijapur 382870, IN
Priority Data
202321041363
17.06.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP India
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1069 | |
| EPO | Filing, Examination | 5071 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 5710 |
Total: 13018 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The presently disclosed subject matter relates to a drug-antagonist combination dosage form, a method for preparing the dosage form, and a method of administering the dosage form to treat a disease or therapeutic condition. The presently disclosed subject matter provides an oral, multi-particulate, extended-release, drug-antagonist combination dosage form comprising one or more drugs and one or more antagonists, wherein the dosage form provides two-stage protection in an overdose condition: the first stage is to retard the release of the drug from the dosage forms, and the second stage is to make the antagonist available in an effective amount if the dosage forms fail to retard the drug release in the overdose condition.[French]
L'objet de la présente divulgation concerne une forme posologique combinant un médicament et un antagoniste, un procédé de préparation de la forme posologique et une méthode d'administration de la forme posologique pour le traitement d'une maladie ou d'une pathologie. La présente invention concerne une forme posologique combinée de médicament et d'antagoniste à libération prolongée, multiparticulaire et orale, comprenant un ou plusieurs médicaments et un ou plusieurs antagonistes, la forme posologique assurant une protection en deux étapes en cas de surdose : la première étape consiste à retarder la libération du médicament à partir des formes posologiques et la seconde étape consiste à rendre l'antagoniste disponible en quantité efficace si les formes posologiques ne parviennent pas à retarder la libération du médicament dans l'état de surdose.